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ABSTRACT 
 
Type 1 diabetes mellitus (T1DM) is an autoimmune disease characterized by abnormal 
carbohydrate metabolism, insulin deficiency and subsequent hyperglycemia. Complications arise 
with poor glycemic control leading to the onset of microvascular and macrovascular diseases. 
Advanced glycation end products (AGEs) associated with hyperglycemia infiltrate microvascular 
tissues, ultimately leading to vascular disease of the nervous system, eyes and kidneys.1 Diabetic 
nephropathy is the leading cause of chronic kidney disease.2 The severity of this autoimmune 
disease is therefore independently and dependently associated with numerous pathologies such 
as cardiovascular disease, vitamin D deficiency and impaired one-carbon metabolism.  
CKD is characterized by structural and functional changes of the glomerulus and renal 
tubules, which results in impaired filtration and reabsorption of various proteins and nutrients 
involved in methyl group metabolism and vitamin D metabolism. Declining glomerular filtration 
associated with renal disease is associated with hyperfiltration of vitamin D binding protein 
(DBP) and 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), disrupting vitamin D status and decreased 
homocysteine clearance and subsequent plasma homocysteine elevation.3-5 Understanding the 
mechanisms that mediate methyl group supply and homocysteine regulation is imperative in the 
prevention and treatment of these interrelated chronic diseases.  
 Alterations in key regulatory proteins within one-carbon metabolism have been observed in 
type 1 diabetes as compensatory mechanisms for disturbed homocysteine levels and methyl 
group supply. Previous research has demonstrated normalization of glycine N-methyltransferase 
(GNMT) and other regulatory proteins associated with administration of insulin, glucocorticoids 
and retinoic acid (RA). These results indicate the potential role of hormonal modulation in 
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regulating one-carbon pathways.6 In addition, we have implemented the use of resistant starch 
(RS) in our laboratory as a therapeutic dietary agent for glycemic control in diabetes. In these 
studies, we have demonstrated the ability of RS to prevent and/or alleviate many DM-related 
complications including weight loss, hyperglycemia and diabetic nephropathy. In addition, RS-
treatment normalized gene expression of proteins involved in vitamin D metabolism.  
 These results have illustrated the protective effect of RS in diabetes, specifically related to 
diabetic nephropathy and associated perturbations in vitamin D metabolism. The goal of this 
study was to investigate the effect of dietary RS in preventing/attenuating abnormalities related 
to diabetes perturbed methyl group metabolism. Furthermore, this study aimed to explore the 
possibility of RS and glucose as potential hormonal and nutritional modulators in methyl group 
metabolism using a streptozotocin (STZ)-induced model of T1DM.   
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CHAPTER 1: LITERATURE REVIEW 
 
Introduction to Type 1 Diabetes Mellitus 
Type 1 diabetes mellitus (T1DM) is a complex autoimmune disease that manifests from a 
combination of genetic, epigenetic and environmental factors.7 This disease is characterized by 
abnormal carbohydrate metabolism and subsequent hyperglycemia due to pancreatic beta (β) cell 
dysfunction and insulin deficiency.8 Traditionally referred to as juvenile diabetes, the highest 
incidence of this disease occurs in children between the ages of 5 and 9 years old.9 While this 
disease occurs most commonly in adolescents, diagnosis of this autoimmune disease is rising 
among all age groups.10 According to the World Health Organization, 180 million individuals are 
living with diabetes and approximately 5-10% (18 million) have T1DM.11  
Carbohydrate metabolism and insulin secretion 
T1DM is a disease that targets the endocrine portion of the pancreas. Pancreatic cells 
pertinent to this autoimmune disease are the β cells within the islet of Langerhans. The islet cells 
are responsible for secreting insulin in response to carbohydrate ingestion, glucose absorption 
and glucose uptake into the pancreas via GLUT transporters. Insulin secretion occurs in two 
separate phases: 1) the triggering pathway and 2) the amplifying pathway . In a positive energy 
state or post-absorption, glucose is transported into the pancreatic β cells by glucose transporters 
(GLUT1 in humans, GLUT2 in rodents) via facilitated diffusion. Glucose is committed to 
various energy pathways, generating adenosine triphosphate (ATP) from glycolysis, Kreb’s cycle 
and the electron transport chain (ETC).12 
Glycolytic enzyme glucokinase (GK) and ATP contribute to pancreatic β cell signaling for 
insulin secretion. Insulin release by the islet cells may be governed by GK, as it participates in 
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the rate-limiting step in the glycolytic energy pathway.13 This enzyme is essential for committing 
glucose to it’s phosphorylated form, for it’s metabolism through glycolysis, the Kreb’s cycle and 
oxidative phosphorylation by the ETC. For this reason, GK is considered a “pacemaker” for a 
variety of metabolic reactions, taking substrate glucose and generating products such as 
pyruvate, lactate, oxaloacetate, citrate, malonyl-CoA, CO2, H20 and ATP.13,14 
Insulin secretion is stimulated by a series of reactions following the generation of ATP by 
these energy pathways. The electron flux produced in the ETC paired with the increased 
ATP/ADP ratio stimulates a rapid change in mitochondrial membrane potential.15 ATP-sensitive 
potassium (K+) channels are modulated by ATP and close in response to higher levels of this 
metabolic end product. Depolarization of the pancreatic β cell triggers the opening of voltage-
dependent calcium (Ca2+) and sodium (Na+) channels, causing a dramatic influx of Ca2+ and 
Na+.12 
Increased concentrations of intracellular Ca2+ signals soluble N-ethylmaleimide-sensitive 
factor attachment protein receptor (SNARE) protein complexes to initiate the translocation of 
insulin-containing secretory vessels to the cellular membrane.16 This results in exocytosis of 
insulin into the bloodstream for glucose homeostasis.15 This event is classified as the triggering 
pathway or the 1st phase of insulin secretion, occurring within the first 10 minutes following 
glucose uptake and beta cell stimulation.16,17 Researchers have proposed that each insulin-
secreting phase utilizes a specific set of insulin granules, the readily releasable pool (RRP) and 
storage-granule pool. Insulin granules docked on the cellular membrane of the β cell are thought 
to be reserved for immediate release during the 1st insulin-secreting phase following glucose 
uptake, while majority (>95%) of insulin granules reside in the intracellular storage pool.12,15,16,18
 Researchers have proposed that the second insulin-secreting phase is initiated by specific 
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amplifying pathways that generate products such as GTP, NADPH, Malonyl CoA, LC Acyl-CoA 
and Glutamate.12,17 The insulin storage-pool is stimulated by these pathways, causing the 
translocation of granules to the cellular membrane. This reserve pool is converted to the RRP and 
stimulated by the depolarized nature of the β cell. Insulin is then released during the second 
insulin-secreting phase. Biphasic insulin secretion allows for both a rapid and steady release of 
insulin into the bloodstream. Hormone insulin binds to insulin receptors throughout circulation, 
signaling GLUT transporters for glucose absorption. GLUT transporters are recruited from the 
intracellular pool and undergo translocation to the cellular membrane for glucose uptake. 
Therefore, insulin is a fundamental part of blood glucose homeostasis.12 This mechanism 
progressively declines with diabetes onset.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Mechanism of glucose absorption and biphasic insulin secretion in beta cells. Glucose enters the 
islet cell via facilitated diffusion for catabolism and ATP production. Depolarization of the cellular membrane by 
ATP and catabolic electron flux leads to the fusion of insulin granules to the membrane for insulin secretion. This 
event occurs in two separate phases characterized by the location of insulin granules to the cellular membrane. 12 
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Etiology 
T1DM manifests from a combination of genetic, epigenetic and environmental factors. 
Recent studies have investigated >50 genetic polymorphisms related to the development of 
T1DM.19 Individuals may possess particular alleles or mutations of the following genes most 
associated with the development of this chronic disease: human leukocyte antigen (HLA), 
insulin, protein tyrosine phosphatase 22 (PTPN22), interleukin-2 receptor (IL2Ra) and cytotoxic 
T-lymphocyte antigen 4 (CTLA4). These susceptibility genes are not sole determinants in 
disease development.20 Research suggests the development of T1DM is dependent on a 
combination of factors including age, family history, genetic susceptibility markers, number of 
autoantibodies and environmental triggers.19  
Longstanding research suggests the greatest genetic influence in T1DM development stems 
from two chromosomal regions: HLA and the insulin gene.21,22 A specific locus found in the 
HLA class II genes on chromosome 6p21 or insulin-dependent diabetes mellitus locus (IDDM1) 
was confirmed as a primary susceptibility gene related to the onset of various autoimmune 
diseases including T1DM. Specifically, recent studies have associated 30-50% of T1DM cases 
with the presence of HLA type II genotypes (MHC Complex).19 While particular haplotypes of 
this gene are considered predisposing alleles, others have been found to be protective in nature. 
HLA-DQB1*0201 and/or HLA DQB1*0302 are associated with T1DM development, whereas 
DRB1*15011, -DQA1*0102, and -DQB1*0602 haplotypes have the strongest negative 
association with the disease.23-25 Predisposing HLA haplotypes may increase the risk of T1DM 
development by up to 55% in adolescents.19 However, the protective alleles are capable of 
“silencing” the high-risk alleles, even in the presence of islet cell antibodies.26 
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Individuals with first-degree relatives that possess the highest risk haplotype have >20% risk 
for T1DM development, while those with no known first-degree relatives with T1DM have a 2% 
risk.19 Individuals that share high-risk HLA genotypes with a diabetic sibling have an 80% risk 
for immunity (IA) and a 60% increased risk for T1DM development. Genetically susceptible 
individuals are particularly vulnerable to environmental triggers that preempt diabetes onset and 
lead to the production of islet autoantibodies (IAA).20 Presence of two or more autoantibodies 
may dramatically increase risk for T1DM, regardless of genetic susceptibility or family history.19 
Researchers have discovered a modest relationship between the insulin gene and T1DM 
compared to the HLA locus.19 Variable number tandem repeat (VNTR) polymorphisms located 
on the promoter region of the insulin gene on chromosome 11 may be involved in the regulation 
of insulin expression in the thymus.20 PTPN22, IL2RA and CTLA-4 susceptibility genes mediate 
Thymus cell (T cell) regulation and other immune related processes.27 Polymorphisms of these 
genes can result in alteration of T cell function, affecting a variety of autoimmune diseases such 
as T1DM, rheumatoid arthritis, celiac disease and Crohn’s disease.19  
Researchers have recently investigated the severity of risk related to the presence of one or 
more of the previously mentioned polymorphisms. In a recent study, researchers worked with a 
combination of different loci including HLA class II genes, insulin gene, PTPN22 and CTLA4. 
Results revealed that the presence of these particular alleles posed a very high risk for T1DM 
development. However, the likelihood of an individual possessing all susceptibility genes is very 
low. Researchers concluded that the presence of high-risk alleles paired with a family history of 
T1DM leads to an increased hazard ratio (HR) for IA and progression of T1DM.19 
While these susceptibility genes can increase an individual’s risk for T1DM development, 
research strongly suggests disease onset involves an environmental trigger or a combination of 
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several. Detectability of this autoimmune disease begins with the presence of four major 
autoantibodies including insulin (IAA), glutamic acid decarboxylase (GADA), the tyrosine 
phosphatases: insulinoma-associated protein 2 (IA-2) and insulinoma-associated 2B (IA2B), and 
zinc transporter 8 (ZnT8A).28 Exposure to specific environmental factors is thought to trigger the 
diabetic autoimmune response. This leads to the progressive destruction of β cells, infiltration of 
IAA into the pancreas causing insulinitis and subsequent perturbation of carbohydrate 
metabolism and hyperglycemia.20 Disease manifestation is variable, lasting up to several years 
before symptoms are clinically diagnosed.  
Several viruses have been linked to T1DM onset but there is insufficient evidence to support 
a causal relationship.20 The most common viruses associated with the development of T1DM are 
enteroviruses or coxsackieviruses. Researchers have proposed that Coxsackievirus B4 (CVB4) 
target β cells and cause insulinitis in genetically susceptible mice.20 Similar evidence was found 
in children that were previously infected with the virus and later developed T1DM. Other 
research studies have reinforced this positive correlation, finding the presence of enteroviruses in 
44 of 72 (approximately 60%) recently diagnosed T1DM patients and only 3 of 50 control 
participants.20 Congenital rubella syndrome and T1DM are positively correlated as evidenced by 
various research studies. Proposed mechanisms suggest that the infection inhibits β cell growth 
and/or increases susceptibility for DM-associated predisposing HLA haplotypes in children.20 
Collective results investigating viral environmental triggers are inconsistent, illustrating the 
variability associated with autoimmune diseases. Ongoing research is being conducted to 
investigate factors such as the amount of time between viral infections and disease onset and the 
presence/absence of insulinitis or autoantibodies prior to viral infection. While a virus may 
trigger the immediate progression of T1DM, researchers also suggest that viruses play a dormant 
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role, initially affecting gut mucosa and later translocating to the pancreas to cause the 
autoimmune event prior to T1DM onset.20 Further research must be conducted to better 
characterize these relationships.  
Researchers are also investigating the role of gut microbial balance and T1DM onset. The 
alteration of microbiota via antibiotics and probiotics may change the immunological tolerance 
of the gut, which may alter the integrity of the immune system and increase an individuals risk 
for autoimmune diseases including T1DM.20 Interestingly, researchers are finding that while gut 
microbiota may play a role in the development of this T1DM, it may also be important in the 
treatment of this autoimmune disease.20 Proposed environmental triggers related to T1DM are 
plentiful, including viruses, bacteria and nutritional components such as cow’s milk, wheat 
proteins, meat nitrites/nitrates and vitamin d. It is unknown whether these factors work together 
or alone in stimulating disease progression. 
 
 
 
 
 
 
 
 
 
Figure 1.2: Factors leading to β  cell failure in type 1 diabetes mellitus onset. Symptoms leading to clinical 
presentation of the autoimmune disease.29  
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Type 1 diabetes onset 
 Researchers have proposed many hypotheses regarding the process of T1DM onset and 
disease development. The most widely accepted is named the linear β-cell decline hypothesis, 
presented by Eisenbarth in 1986. This model illustrates the presence of genetic susceptibility 
markers and an environmental trigger, leading to the production of IAA, insulinitis and 
progressive loss of β cell mass (Figure 1.2). This event eventually leads to clinical onset as 
identified by uncontrolled hyperglycemia and other characteristic diabetic symptoms. 12  
Beta cell mass describes the number and size of these pancreatic cells. In normal 
individuals, β cell mass progressively increases from birth and throughout adolescence, reaching 
peak mass in early adulthood and then declining with age. Diabetic individuals experience a 
more rapid decline in β cell mass in conjunction with IAA production and insulinitis, most often 
at a younger age. Clinical diagnosis occurs after the loss of 70-80% of β cell mass. The timeline 
for disease manifestation is largely variable, progressing over a period of months to several years 
depending on the individual. Clinical onset is determined by the presence of uncontrolled fasting 
blood glucose and other symptoms of T1DM including polyuria, polydipsia, polyphagia, weight 
loss, fatigue, and ketoacidosis in severe cases.12  
 β cell death occurs following an autoimmune reaction that may be initiated by viral 
infections or inflammation causing endoplasmic reticulum (ER) stress in the pancreas. Beta cell 
apoptosis may then cause secretion of β-cell antigens, tumor necrosis factor alpha (TNFα) and 
interferon (IFN-γ). The release of these antigens from necrotic β cells stimulates antigen-
presenting cells (APC’s) to activate naïve T cells in the pancreatic lymph nodes. Active T-cells 
will then remain in the islet cells of the pancreas, releasing inflammatory cytokines and 
contributing to pancreatic insulinitis upon reexposure to these β cell antigens. Inflammatory 
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cytokines stimulate transcription factors nuclear factor kappa beta (NFχβ) and signal transducer 
and activator of transcription 1 (STAT-1). This process causes ER stress, amplified release of 
cytokines and disruption of proteins responsible for regulating insulin production and secretion.12 
Research also suggests that islet cells are more vulnerable to oxidative stress in comparison to 
other bodily tissues. Circulating cytotoxic free radicals and nitric oxide (NO) may contribute to 
islet cell damage.30,31 Collectively, this process seems to be a cycle of reactions leading to the 
progressive destruction of pancreatic β cells, insulinitis and development of type 1 diabetes.12  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Autoimmune response and β  cell apoptosis. Induction and progression of insulitis and loss of beta 
cell mass by an autoimmune inflammatory cascade12 
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Clinical symptoms and disease complications  
Increased presence of autoantibodies normally precedes the diagnostic symptoms associated 
with T1DM, with autoantibodies present in 85-90% of patients upon diagnosis.32 Clinical 
diagnosis of T1DM is characterized by elevated fasting blood glucose (FBG; >126 mg/dL) 
caused by impaired insulin secretion and abnormal carbohydrate metabolism. Synthetic insulin 
administration is needed in order to keep blood glucose in homeostatic conditions (70-100 
mg/dL)33 and prevent common symptoms of diabetes seen in newly diagnosed patients. 
Uncontrolled hyperglycemia can lead to various clinical indicators including polyuria, 
polydipsia, polyphagia, weight loss and diabetic ketoacidosis in severe circumstances.32 When 
blood glucose exceeds the renal “glucose load” of 180 mg/dL, glucose spills over into the urine 
causing osmotic diuresis. Water and other solutes move from a lower concentration to a higher 
concentration, following large glucose molecules to be excreted as urine. Polyuria or increased 
urinary excretion and elevated excretion of solutes lead to dehydration and increased thirst 
(polydipsia). Research consensus has deemed weight loss, polyuria and polydipsia the most 
common symptoms associated with T1DM onset.34   
Aberrant carbohydrate metabolism forces the body to revert to other energy pathways to 
maintain body functioning, such as gluconeogenesis and lipolysis. The breakdown of 
triglycerides to free fatty acids leads to rapid weight loss and increased hunger (polyphagia).35 
Prolonged hyperglycemia and dependence on lipolysis metabolism can lead to the accumulation 
of acetyl-CoA, leading to ketone production and elevated ketone bodies in the blood and urine. 
Diabetic ketoacidosis (DKA) is characterized by low blood pH, with a pH 7.1-7.35 or plasma 
bicarbonate 10-21 mmol/L classifying mild to moderate DKA and a pH of <7.10 and plasma 
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bicarbonate <10 mmol/L classifying severe DKA.34 Presence of DKA can dramatically increase 
an individual’s risk for neurological damage, hyperglycemic coma or death.  
Synthetic insulin administration is the primary treatment utilized by T1DM patients to keep 
blood glucose at homeostasis and allow for normalized metabolism. Prolonged uncontrolled 
hyperglycemia can lead to a multitude of adverse health effects including both microvascular and 
macrovascular complications. Hemoglobin AIC is a standard biomarker used to assess long-term 
glycemic control, aiding in diabetes management and prevention of complications.32 The primary 
microvascular complications associated with this disease are diabetic retinopathy, nephropathy 
and neuropathy.  These complications are preceded by biomarkers and structural changes such as 
increased excretion of albumin (microalbuminuria) and declining glomerular filtration rate 
(GFR), renal hypertrophy, declining autonomic nervous system function and altered retinal 
microvasculature.36 
  Chronic hyperglycemia can drastically alter the extracellular and intracellular structure and 
function of many body tissues. Uncontrolled blood glucose leads to the formation of advanced 
glycation end products (AGEs) when glucose molecules target nucleic acids, lipids and proteins 
causing glycation and oxidation of these macromolecules. AGEs accumulate in vascular tissues 
and are therefore indicative in the pathophysiology of microvascular and macrovascular 
complications associated with diabetes.1 These compounds are capable of altering intracellular 
protein function, disturbing gene expression, releasing pro-inflammatory cytokines and free 
radicals and irreversibly modifying the extracellular matrix.37  
AGEs form reactive oxygen species (ROS), which bind to cellular receptors to initiate cross-
linking at the extracellular matrix (ECM). AGEs may form cross-links with large matrix 
molecules such as collagen and elastin, causing increased surface area of the matrix and a more 
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rigid vasculature. Accumulation of AGEs can trigger the receptor for advanced glycation end 
products (RAGE), which increases endothelial permeability to larger solutes in the vasculature.1 
RAGE also targets smooth muscle cells, macrophages and proteins related to low-density 
lipoprotein (LDL) oxidation. Collectively, these alterations contribute to the formation of 
atherosclerotic lesions, rigidity of arterial walls, decreased elasticity of blood vessels, and 
therefore increased risk for atheromas and myocardial infarction.38 These structural changes 
increase the incidence of hypertension (HTN) and together characterize cardiovascular disease 
(CVD).   
Diabetic retinopathy is characterized by structural changes to the retinal basement 
membrane, vascular occlusion and hyperpermeability of capillaries causing vascular leakage 
associated with the accumulation of AGEs. Diabetic retinopathy is the leading cause of 
blindness, while also contributing to cataract formation, microaneurysyms and hemorrhages. 
Diagnostic symptoms of diabetic neuropathy include pain or numbness of extremities and 
declining nerve and sensory motor function. Myelin is vulnerable to glycation by AGE’s in 
uncontrolled diabetes, causing demyelination in addition to nerve conduction occlusion.36 
Diabetic nephropathy is the primary cause of renal failure and is characterized by declining 
GFR, thickening of the glomerular basement membrane and proteinuria.2 Accumulation of AGEs 
in the renal vasculature contributes to the structural and functional changes of the glomerulus by 
stimulating the release of growth factors that initiate synthesis of collagen and other ECM 
proteins. The progressive thickening of the basement membrane eventually leads to renal 
filtration dysfunction, HTN and kidney failure. Structural damage to the nephrons paired with 
increased vascular permeability leads to hyperfiltration of small molecular weight proteins such 
as albumin and many other nutrients.5 
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Declining GFR is associated with a multitude of adverse health effects including HTN, 
anemia, malnutrition, bone disease, neuropathy and CVD. Declining GFR and proteinuria 
(microalbuminuria/macroalbuminuria) are used to identify the progression of diabetic 
nephropathy or chronic kidney disease (CKD) to renal failure.37 These biomarkers are indicative 
of renal function and widely used in classifying the severity of chronic kidney disease by 
appropriate stages. Albumin is a large circulating protein, used as a sensitive biomarker for 
various disease states including malnutrition, diabetes, glomerular disease and HTN. Creatinine 
is an additional biomarker used widely to assess GFR and CKD appropriately. The ratio of 
albumin:creatinine is highly predictive in renal disease classification, with a ratio of >30 mg 
albumin/1 g of creatinine indicating kidney damage as a result of poor glycemic control and 
disease progression.39,40  
Urinary albumin excretion (UAE) is classified as microalbuminuria at 20-200 µg/min and 
macroalbuminuria at ≥200 µg/min.41 Albuminuria is present during the early stages of CKD with 
GFR between 60-90 mL/min/1.73 m2. Moderate (stage 3) to severe (stage 4) CKD is classified 
by a GFR of 30-59 and 15-29 mL/min/1.73 m2, with renal failure occurring when GFR falls 
below 15 mL/min/1.73 m2.42 Normal serum creatinine concentrations are between 0.8-1.4 mg/dL 
in men and 0.6-1.2 mg/dL in women, with creatinine levels between 1.3-3.0 mg/dL indicating 
diabetic nephropathy.2,43 Collectively, GFR and related proteins are used regularly to determine 
disease severity in order to develop and implement appropriate pharmaceutical and behavioral 
treatment methods for diabetic patients.  
Diabetes is the leading cause of CKD, with approximately 40% of diabetic individuals 
progressing from diabetic nephropathy to CKD and end stage renal failure (ESRF).41 CKD and 
subsequent HTN are strongly associated with CVD, presenting an increased risk for stroke, 
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peripheral artery disease, coronary heart disease, atrial fibrillation and heart failure. CVD 
mortality is inversely related to GFR or severity of renal impairment, accounting for 58% of 
deaths in CKD patients in a Canadian cohort study and 71% of deaths in a Taiwanese cohort.5 
 Mechanisms linking CKD and CVD are plentiful and many are independent of HTN, 
diabetes and other traditional risk factors. Researchers postulate that left ventricular hypertrophy 
(LVH) associated with HTN, renal anemia, vascular rigidity and underexpression of coronary 
endothelial regulatory proteins, may be responsible for increased CVD risk. LVH can lead to 
reduced cardiac reserve and impaired myocardial contractility, which may be attributed to 
impaired coronary dilation and reduced capillary density.44  
Other factors leading to CKD-associated heart disease include dyslipidemia, inflammation, 
metabolic byproducts and alteration of the renin-angiotensin system.44 CKD-induced 
dyslipidemia results from secondary hyperthyroidism and perturbed gene regulation in lipid 
metabolism, resulting in downregulation of lipoprotein lipase, upregulation of lipase inhibitor 
Apolipoprotein C-III and reduced catabolism and clearance of lipoproteins. The disruption of 
low-density lipoprotein (LDL) receptor and acyl-coenzyme A cholesterol acyltransferase 
(ACAT) has also been correlated with the impaired lipid metabolism and accumulation of LDL-
cholesterol in the serum. Together, these alterations lead to LDL oxidation in blood vessels, 
leading to the inflammatory cascade that preempts the formation of atheromas.45  
Increased oxidative stress is characterized by elevated levels of ROS and is associated with 
the accumulation of AGEs in diabetes and activation of the renin-angiotensin system in CKD.46 
Angiotensin II stimulates enzymatic systems such as NADPH oxidase, generating ROS, 
inflammatory cytokines and chemokines, and other molecules involved in the atherosclerotic 
inflammatory cascade.5 Circulating ROS directly affects endothelial function, resulting in 
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functionality changes and hyperpermeability of the vascular endothelium. This allows for the 
passage of LDL molecules into the blood vessels for lipid oxidation, further stimulating 
inflammatory processes and the formation of atherosclerotic lesions.46  
CKD can lead to various health effects aside from CVD, including anemia, bone and 
mineral disease and malnutrition.47 Declining renal function causes hyperfiltration of proteins 
and other nutrients such as vitamin D. Increased urinary excretion of 1,25-dihydroxyvitamin D3 
(1,25(OH)2 D3; calcitriol), the major circulating form of this nutrient, leads to decreased calcium 
absorption and subsequent hypocalcemia, secondary hyperparathyroidism and renal 
osteodystrophy.48 The role of vitamin D associated with T1DM is extensive, as deficiency of this 
nutrient may associate with disease onset and/or be affected by the disease itself.  
Introduction to Vitamin D 
Vitamin D deficiency is associated with many pathologies including CVD, osteoporosis and 
other adverse bone diseases, cancer, neurological disorders, CKD and autoimmune diseases. A 
multitude of research has been geared toward understanding the relationship between vitamin D 
deficiency and these known pathological conditions.49 Current literature supports the link 
between vitamin D deficiency and T1DM. Interestingly, research has investigated two scenarios 
regarding this relationship. Does the autoimmune disease cause vitamin D deficiency or does the 
nutrient deficiency exacerbate the autoimmune event that leads to the onset of this disease? 
Vitamin D and its immunomodulatory role in type 1 diabetes progression 
Vitamin D plays an immunomodulatory role in the prevention of this autoimmune disease as 
evidenced by the presence of the vitamin D receptor (VDR) in APC’s, active T cells and 
pancreatic β cells. Studies using a non-obese diabetic (NOD) model of T1DM, found that 
vitamin D deficient mice were more likely to develop the disease. The autoimmune event was 
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exacerbated in mice that were vitamin D deficient earlier on, suggesting that nutrient 
homeostasis may be imperative during childhood, especially in individuals with genetic 
predisposition to the disease. Additionally, vitamin D supplementation in NOD mice reduced the 
severity of symptoms characteristic of the diabetic state, preserved β cell function and 
prevented/attenuated clinical onset.48,50,51 While many studies have shown supplementation to be 
beneficial, others have proven these positive effects are only achievable if the rodent or 
individual is initially vitamin D deficient. 
  The mechanism by which vitamin D deficiency stimulates T1DM progression involves a 
variety of processes regulated by VDR in the pancreas and 1,25 (OH)2D3 throughout the immune 
system. 1,25 (OH)2D3 exhibits protective effects in the pancreatic islet cells, inhibiting the 
production of inflammatory cytokines and chemokines, increasing regulatory immune cells, 
decreasing T cell activation and infiltration and downregulating MHC II proteins involved in 
cytotoxic T cell recruitment. Additionally, 1,25 (OH)2D3 prevents beta cell apoptosis through 
several mechanisms including 1) downregulation of A20 protein gene related to NO production 
and the subsequent production of inflammatory factors 2) stimulation of dendritic cell turnover, 
preventing differentiation and maturation into APC’s that preempts the autoimmune event 
observed T1DM onset and 3) direct inhibition of IL-6 inflammatory cytokines.50 A 2004 study 
implemented a vitamin D deficient diet in pregnant NOD mice, acclimated offspring to this diet 
following birth for 100 days and analyzed the immune system. Vitamin D deficient NOD mice 
were found to have extreme abnormalities in macrophage cytokine profiles and elevated 
circulating proinflammatory factors, leading to aggressive disease progression.52 Given its 
imperative immunological role, vitamin D may act as an environmental modulator in the 
prevention or progression of T1DM.52  
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Overview of vitamin D metabolism 
 Vitamin D3 (cholecalciferol) can be obtained in the diet or be synthesized in the skin via 
ultraviolet radiation. Ultraviolet B (UVB) photons penetrate the epidermis and dermis layers of 
the skin to activate pre-vitamin D3 (7-dehydrocholesterol) to vitamin D3. Vitamin D3 is 
transported through circulation via vitamin D binding protein (DBP) for hydroxylation in the 
liver, resulting in 25-hydroxyvitamin D3 (25(OH)D3; calcidiol), the major circulating form of 
vitamin D in the body. Clinically, this form of vitamin D is the best reflection of vitamin D 
status. DBP then transports 25(OH)D3 to cellular tissues for uptake and utilization.53 In the 
kidney, the DBP-25(OH)D3 complex is filtered across the glomerulus where it then binds to the 
cellular membrane of the proximal renal tubule, activating endocytic receptors megalin, cubilin 
and disabled-2 (dab-2) proteins for reabsorption. There, 25(OH)D3 is further hydroxylated by 1α-
hydroxylase to form biologically active 1,25(OH)2D3.54  
Vitamin D and type 1 diabetes 
 Structural and functional changes in the kidneys associated with diabetic nephropathy can 
dramatically alter filtration and appropriate reabsorption of nutrients, affecting vitamin D status. 
The megalin-cubilin complex is responsible for reabsorption of many proteins and nutrients 
including DBP and 25(OH)D3. Previous studies using megalin-knockout mice observed 
increased excretion of DBP, 25(OH)D3, albumin and other low-molecular weight proteins.54 
Similar results have been observed in T1DM animal models, with positive correlations between 
chronic hyperglycemia and DBP excretion.4 Streptozotocin (STZ)-induced models of T1DM 
have confirmed these hypotheses, observing decreased expression of megalin in the proximal 
tubules and increased urinary excretion of megalin, cubilin and DBP.55  
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 Additional studies have observed increased expression of renal 1α-hydroxylase as a 
compensatory mechanism to maintain vitamin D status in diabetic rodent models. However, the 
upregulation of this hydroxylase enzyme was typically associated with decreased 1,25(OH)D3 
concentrations due to 25(OH)D3 deficiency, the substrate for 1,25(OH)D3 activation. 
Collectively, the results suggests that the progression of diabetic nephropathy leads to the 
downregulation and excretion of endocytic receptors, causing the impaired reabsorption of DBP 
and 25(OH)D3, resulting in vitamin D deficiency.54 
Introduction to Methyl Group Metabolism 
 Folate, homocysteine and methyl group metabolism are interrelated pathways that 
encompass one-carbon metabolism.56 Together these pathways regulate methyl group supply for 
a multitude of cellular pathways and metabolic reactions. One-carbon methyl groups are 
essential for over 100 transmethylation reactions and play a key role in DNA methylation and 
regulation of gene expression. The disruption of these pathways is related to a variety of 
pathologies including birth defects, CVD, osteoporosis, neurological disorders, cancer, metabolic 
syndrome and vascular diseases.57,58 Understanding the mechanism by which these pathways are 
perturbed may provide a sound link between chronic disease and associated complications. 
Methionine, folate, betaine and choline act as methyl donors, transferring one-carbon units 
throughout four regulating pathways within methyl group metabolism. Transmethylation, 
transsulfuration, folate-independent remethylation and folate-dependent remethylation mediate 
methyl group supply and homocysteine metabolism. These pathways are regulated by a variety 
of mechanisms to fuel transmethylation reactions that require an adequate supply of methyl 
groups. This section of the literature review will summarize each of these pathways and highlight 
the key metabolic steps affected by the diabetic state.  
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Figure 1.3: One carbon methyl group metabolism and folate metabolism. Methionine is converted to 
homocysteine in the transmethylation pathway. Homocysteine can be remethylated to methionine via folate-
dependent or folate-independent mechanisms. 59 
 
Transmethylation 
The transmethylation pathway is present in most bodily tissues, beginning with an ATP-
dependent reaction catalyzed by methionine adenosyltransferase (MAT). MAT is a tissue-
specific enzyme that is expressed by three separate isoforms. MAT I and III are solely expressed 
in the liver, while MAT II is functional in most tissues.60 This enzyme donates an adenosyl group 
to the amino acid methionine to form S-adenosylmethionine (SAM). Methyltransferases (MTs) 
mediate methyl group transfer from SAM to a variety of substrates including lipids, proteins, 
nucleic acids and neurotransmitters.61,62 A methylated product and S-adenosylhomocysteine 
(SAH), a competitive inhibitor of MTs are generated following methyl group removal from 
SAM. SAH is then hydrolyzed to form homocysteine and adenosine via S-adenosylhomocysteine 
hydrolase (SAHH).62,63 
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Methylated substrates formed through the transmethylation pathway are imperative for a 
variety of cellular processes. Methylated lipids are essential components to the structural 
integrity of cellular walls, bile formation and cellular signaling,64 while methylation of proteins 
stimulates protein activation via post-translational modification. Methylated proteins are 
functional in cellular signaling, transcription and gene regulation.65 Nucleic acids comprised of 
ribonucleic acids (RNA) and deoxyribonucleic acid (DNA) are methylated in this pathway and 
are vital in regulating gene expression.66 Epigenetic modifications of methylated substrates have 
been directly correlated with the development of numerous pathological conditions including 
cancer, CVD and autoimmune diseases.67 Therefore, it is crucial to ensure adequate methyl 
group supply and promote homeostasis of key proteins within one-carbon metabolism.   
Transmethylation is dependent on and regulated by a variety of mechanisms, including 
allosteric regulation via SAM:SAH ratio and the action of specific regulatory proteins in 
response to this ratio.59 The ratio of SAM:SAH in the transmethylation pathway influences  
homocysteine levels, methyl group usage and the pathways utilized in methyl group metabolism. 
Elevated concentrations of either compound can result in inhibition of processes regulated by it’s 
counterpart. Elevated SAH concentrations inhibit SAM-dependent reactions, potentiating 
disturbed methyl group maintenance. Conflicting results have been found regarding the 
relationship between SAH and hypomethylation, suggesting the multitude of factors involved in 
regulating these metabolic pathways.61 Increased concentrations of SAM 1) stimulate the 
catabolism of homocysteine to cysteine via cystathionine beta synthase (CBS), utilizing the 
transsulfuration pathway and 2) allosterically inhibit 5-CH3-THF, preventing folate-dependent 
remethylation when SAM concentrations are sufficient. These mechanisms promote SAM:SAH 
homeostasis, homocysteine regulation and conserve methionine for vital methylation reactions.56 
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The transmethylation pathway utilizes three primary methyltransferase proteins to regulate 
methyl group metabolism and homocysteine concentrations.62 Glycine N-methyltransferase 
(GNMT) is an enzyme that accepts and catabolizes adenosine to sarcosine, a metabolite with no 
known metabolic role.56 This mechanism provides a pathway to discard excess methyl groups 
which can help regulate SAM:SAH ratio and/or lead to hypomethylation.61 Enzymes that assist 
to yield SAH include phospatidylethanolamine N-methyl transferase (PEMT) and 
guanidinoacetate N-methyltransferase (GAMT), forming physphatidylcholine and creatine, 
respectively.62 These proteins are the largest known methyl consumers and therefore, vital in 
regulating homocysteine concentrations.59 
Folate-dependent remethylation 
Two separate pathways, folate-dependent remethylation and folate-independent 
remethylation pathways can generate methionine from homocysteine. The folate-dependent 
pathway utilizes methionine synthase (MS), a B12 dependent protein to catalyze the 
remethylation of homocysteine with the addition of a methyl group donated by folate derivative, 
5-methyltetrahydrofolate (5-CH3-THF). Coenzyme FADH2 assists coenzyme 
methylenetetrahydrofolate reductase (MTHFR), to reduce 5,10 methylenetetrahydrofolate (5,10-
CH3-THF) to 5-CH3-THF in this rate-limiting irreversible reaction. Remethylation of 
homocysteine results in the formation of methionine and tetrahydrofolate (THF).56  
Allosteric regulation allows for these interrelated pathways to maximize methyl group 
supply, while also normalizing homocysteine and other key proteins throughout methyl group 
metabolism. Elevated methyl group supply and SAM concentrations inhibit the activity of 
MTHFR, preventing the formation of methyl donor 5-CH3-THF and downregulating the folate-
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dependent remethylation pathway. Conversely, when methyl group supply is depleted and SAM 
concentrations are low, MTHFR is upregulated allowing for remethylation of homocysteine.58,68 
Folate-independent remethylation 
Folate-independent remethylation is an alternative pathway used to regenerate methionine 
from homocysteine. This utilization of this pathway depends on the dietary protein intake that 
corresponds to methionine concentrations and methyl group supply, SAM:SAH ratio and the 
availability of vitamins B12, B6 and folate. Choline is an essential nutrient that may be oxidized 
in the body via choline oxidase/dehydrogenase to form metabolite betaine, the methyl donor in 
the folate-independent remethylation of homocysteine to methionine.63 Betaine-homocysteine S-
methyltransferase (BHMT), a protein primarily expressed in mammalian hepatic tissue, accepts 
and transfers methyl groups from betaine to homocysteine when methyl groups are depleted and 
SAM concentrations are low.60 This pathway is highly favored when B vitamins are not available 
to fuel folate-dependent remethylation. However, BHMT is allosterically inhibited by SAM 
when methyl group supply is sufficient and SAM:SAH ratio is near homeostasis.69 Collectively, 
these pathways work in sync to maintain vital methylation reactions and promote optimal body 
functioning. 
Transsulfuration  
Transsulfuration is a B6-dependent irreversible metabolic pathway that is upregulated in 
correlation with elevated homocysteine levels. This allosteric mechanism allows for the 
catabolism of homocysteine in the event of elevated methionine levels, folate/B12 deficiency 
and/or the physiological need for cysteine, it’s catabolic product. Transsulfuration is active in the 
liver, kidney, pancreas, intestine and brain.60 Altered expression and activity of key 
transsulfuration enzymes CBS and γ-cystathionase have been observed in tissues specific to 
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diabetes. These observations may be largely due to the hyperhomocystenemic state characteristic 
of T1DM development and severity of CKD.6  
Disruption of methyl group metabolism and pathological implications 
 Research has proven the importance of methyl group maintenance in preventing the 
occurrence of disease. Maintenance of methyl group metabolism is affected by numerous factors 
including the following 1) dietary protein deficiency, which reflects methionine concentrations 
and methyl group supply 2) deficiencies of specific nutrients that fuel one-carbon metabolism 
(i.e. choline, folate, B6, B12)70 3) medications 4) environmental toxins 5) genetic polymorphisms 
of one-carbon metabolic enzymes and 6) complications associated with metabolic diseases.71  
 Disturbed methylation directly alters gene expression, which may lead to a multitude of 
health disparities. Undermethylation of DNA typically leads to overexpression of genes, while 
elevated methylation causes gene silencing. Altered gene expression due to undermethylated 
DNA has been suggested to increase the incidence of oncogenes.56 Several studies have found a 
strong correlation between methyl group deficient diets and the increased expression of 
carcinogens leading to hepatocellular cancer. Wagner et al. identified a 51% increase in 
carcinogenic liver cells in rats fed methionine and choline deficient diets for 13 to 24 months.68
 The body responds to methyl group deficiency by downregulating GNMT enzyme, 
preserving SAM-donated methyl groups for essential methylation reactions when methionine and 
SAM concentrations are low. Research studies have also supplemented homocysteine in 
conjunction with methyl-deficient diets to determine if remethylation of homocysteine would 
provide sufficient methionine to promote methyl group maintenance. Consensus of these results 
is that while homocystiene can be used to regenerate methionine, methyl group deficient diets 
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decrease growth in rats, suggesting that remethylation has a limited capacity for maintaining vital 
methylation reactions.72,73 
 Other studies have investigated the effects of methyl and folate deficient diets in methyl 
group metabolism. Deficiencies of nutrients essential to one-carbon metabolism are highly 
associated with perturbed central nervous system functioning and progression of neurological 
disorders. Additionally, B vitamin deficiencies may lead to depression, birth defects, anemia and 
CVD related to hyperhomocystemia. Folate and methyl deficient diets in rats have caused 
accumulation of homocysteine in the brain as a result of perturbed remethylation and 
transsulfuration pathways in one-carbon metabolism. Elevated homocysteine levels and methyl 
deficiency induced oxidative damage may be indicative in the etiology of CVD and 
neurodegenerative disorders including Alzheimer’s disease, Parkinson’s disease, Huntington’s 
disease and amyotropic lateral sclerosis.70 
 Plasma homocysteine levels between 5-15 µmol/L are considered normal in humans.74 
Hyperhomocystenemia is categorized based on severity, with moderate  (>10µmol/L), 
intermediate (>30 µmol/L) and severe (>100 µmol/L) classifications.3 Homocysteine levels are 
affected by numerous factors including age, sex, smoking, medications, and many disease states, 
especially those associated with impaired renal function. Homocysteine concentrations are 
typically higher in men compared to women and progressively increase with age in both sexes.75 
A parallel relationship between smoking and elevated plasma homocysteine has been replicated 
in many studies. Researchers propose that this relationship may be attributed to impaired vitamin 
B6 status and subsequent perturbation of the transsulfuration pathway, causing homocysteine 
accumulation.75  
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A variety of drug-nutrient interactions impact homocysteine concentrations due to their 
affect on vitamin absorption and disturbance of one-carbon metabolism and folate metabolism. 
Medications used to treat high blood cholesterol and non-insulin dependent diabetes including 
cholestyramine and metformin, interfere with absorption of B vitamins, essential for maintaining 
metabolic pathways associated with homocysteine regulation. Other drugs such as methotrexate, 
fibric acid and nicotinic acid are also associated with elevated homocysteine levels.76 A 2001 
study observed a 53-57% increase in plasma homocysteine levels in patients treated with 
ciprofibrate for hypertriglyceridemia.77 Patients are urged to take caution with any of these 
prescriptions, as hyperhomocysteinemia can lead to many adverse health affects including CVD.  
 Various genetic polymorphisms influence methyl group metabolism, altering methylation 
reactions and homocysteine levels. MTHFR genetic mutations are highly associated with 
hyperhomocystenemia and considered genetic risk factors for CVD.  The primary MTHFR 
mutation is the C667T variant and is characterized by the accumulation of 5-CH3-THF, 
inhibiting the folate-dependent remethylation pathway for regeneration of methionine from 
homocysteine.78 “Methyl trapping” is commonly observed in individuals with this genetic 
mutation and is exacerbated by B vitamin deficiencies, inhibiting folate-independent 
remethylation of methionine via MS enzyme and catabolism of homocysteine via 
transsulfuration.79 Less common one-carbon mutations related to hyperhomocysteinemia include 
transsulfuration proteins, CBS and γ-cystathionase.80 
Methyl group metabolism and type 1 diabetes 
One of the largest determinants in total plasma homocysteine is renal function as illustrated 
by the inverse relationship between GFR and homocysteine. This is one of the strongest links 
between two detrimental chronic diseases, T1DM and CVD. The kidneys play a key role in 
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reuptake of many nutrients including amino acids and their metabolites. The exact mechanism by 
which the kidney functions in homocysteine metabolism and clearance has not been confirmed. 
However, researchers postulate that homocysteine filtration is similar to that of cysteine, lysine, 
arginine and other amino acids. Therefore, impairment of glomerular filtration associated with 
renal disease may cause decreased homocysteine clearance and subsequent plasma homocysteine 
elevation. Some researchers have suggested that in the event of renal impairment, homocysteine-
regulating enzymes are hormonally upregulated to maintain normal plasma homocysteine 
levels.3  
T1DM is typically associated with hyperhomocystenemia as a result these mechanisms. 
However, previous studies have identified hypohomocystenemia in STZ-induced diabetic rodent 
models. While counterintuitive, the mechanism for lower circulating plasma homocysteine 
concentrations may be attributed to compensatory increases in one-carbon metabolic enzymes, 
CBS and γ-cystathionase. These proteins fuel transsulfuration, an alternative metabolic pathway 
capable of catabolizing homocysteine when concentrations are elevated.59 Lower circulating 
concentrations of homocysteine have been observed in T1DM patients in the early stages of the 
disease, characterized by the absence of microvascular complications. Hyperhomocystenemia 
and downregulation of transmethylation and transsulfuration pathways was assessed in 
concurrence with CKD progression.81,82 These results indicate that homocysteine regulation is 
largely dependent on disease severity and functionality of one-carbon metabolic pathways to 
keep homocysteine in homeostatic conditions and maintain methylation reactions.     
Various proteins throughout one carbon methyl group and folate metabolism mediate plasma 
homocysteine concentrations and alterations of these proteins have been observed in T1DM.  
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Perturbed methyl group metabolism has been observed using rodent models of T1DM, indicated 
by the upregulation of GNMT, CBS and γ-cysthathionase and BHMT, enzymes present in 
transmethylation, transsulfuration and folate-independent pathways.6 These enzymes play a key 
regulatory role in homocysteine regulation and methyl group maintenance. Alterations in protein 
expression may indicate the presence of nutritional and/or hormonal modulation of these 
enzymes associated with the diabetic state.6  
Our previous research has demonstrated retinoic acid (RA) and dexamethasone (DEX) as 
independent signals in GNMT induction in a STZ-treated rat model. Insulin administration 
alleviated GNMT upregulation in this diabetic model, suggesting its role as a hormonal 
modulator of regulatory methyl group metabolism proteins.6 However, we would also like to 
explore the possibility of glucose as an independent signal for GNMT induction and other 
associated homocysteine-regulatory proteins. Hormone insulin functions to regulate postprandial 
blood glucose.12 Therefore, normalization of GNMT could be attributed to the administration of 
insulin and/or achieving blood glucose homeostasis.  
Taken together, the goal of this experimental study was to investigate the effect of dietary 
resistant starch (RS) in attenuating hyperglycemia in diabetes, as a means to prevent disease 
complications and associated perturbations in methyl group metabolism. In addition, this study 
aims to investigate RS and glucose as potential hormonal and nutritional modulators in methyl 
group metabolism using a STZ-induced model of T1DM.  
Resistant Starch 
Starch background 
Starch is a type of polysaccharide and a primary source of carbohydrates. This 
polysaccharide is made up of monosaccharides linked together by ∝-D-(1,4) and ∝-D-(1,6) 
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glycosidic linkages. Starch is comprised of two primary molecules, amylose and amylopectin. 
Amylose and amylopectin differ both in structure and digestibility. Amylose is a linear polymer 
chain of glucose molecules connected via ∝-D-(1,4) glycosidic linkages, which typically 
constitutes 25% of starch. Amylopectin is a highly branched glucose molecule that is linked by 
both ∝-D-(1,4) and ∝-D-(1,6) glycosidic linkages making up the remaining 75% of this 
carbohydrate.83,84 
Starch is digested by ∝amylases found in the saliva, pancreas and small intestine. The 
branching of glucose molecules in amylopectin allows for increased enzymatic action and 
therefore more efficient digestibility than amylose.84 Advances in biotechnology have geared 
toward improving the structure, functionality and yield of different starches. Altering genotypes 
of native starches has resulted in the amplified production of high quality crops. Biotechnology 
has allowed for researchers to better understand how functionality and structure affect digestion 
and overall health.83 
Digestibility of starch depends on the chemical makeup of the particular molecule, which 
determines the functional characteristics. Resistant starches are found in nature and can be 
synthetically developed via gene alteration. RS cannot be digested by the ∝-amylases that reside 
in the saliva and throughout the gastrointestinal tract. Therefore, these starches completely or 
partially bypass the small intestine for fermentation in the large intestine. Research has shown 
evidence of prebiotic health benefits associated with consumption of this product. Colonic 
fermentation seems to produce specific metabolites that have been associated with many health 
benefits including normalization of macronutrient metabolism, reduction in colonic carcinogenic 
precursers and hormonal regulation resulting in potential mental and physical health benefits.85  
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Definition and classifications of resistant starch          
 RS is divided among 5 subcategories referred to as RSI, RSII, RSIII, RSIV and RSV. RS1 is 
a type of starch that is structurally protected by a strong protein complex and a dense cell wall, 
inhibiting water absorption and gelatinization and therefore preventing appropriate enzymatic 
action, digestion and absorption in the small intestine.85 RSII is crystalline in structure and 
resistant to enzymatic hydrolysis in an uncooked state. Examples of RSII sources include potato 
starch, green banana starch, gingko starch and high amylose maize starch.83,85 RSIII becomes 
resistant following retrogradation at refrigeration temperatures (4-5°C). This phenomenon causes 
amylose and amylopectin to form of double helices, shortening the chain length of these 
molecules and inhibiting water binding and enzymatic hydrolysis. RSIV is formed via chemical 
modification, which can implement cross-linking throughout the molecule. Cross-linking can 
inhibit both water absorption and enzymatic action by amylases, causing a resistant effect during 
digestion and fermentation. RSV is a thermally stable product that is formed when starch and 
lipid molecules interact. This interaction causes the formation of a helical amylose-lipid 
complex, preventing water absorption and swelling and enzymatic hydrolysis.85  
Resistant starch: applications in health and disease 
 Amylose constitutes approximately 20-35% of naturally occurring maize, with high amylose 
starches comprising greater than 40%.86 Breeding of high amylose starch has been 
commercialized and widely utilized in research, with amylose contents exceeding 90% of total 
composition. Resistant starches have confirmed positive physiological effects according to 
numerous research studies. RS may play an important role in the prevention of colon cancer and 
gallstone formation, improvement of blood lipid profiles and treatment of gastrointestinal 
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diseases and diabetes. Other studies have shown that RS may attenuate fat accumulation and 
increase absorption of key minerals such as calcium and iron.84  
Resistant starch and glycemic control in diabetes 
RS has been investigated as a known hypoglycemic agent that can be implemented for 
therapeutic uses in the treatment of diabetes. Typically, the digestion of starch begins 
immediately following consumption of carbohydrate meals. However, RS is digested at a slower 
rate, taking between 5-7 hours to reach the large intestine. The rate of digestion and absorption of 
glucose is slower following RS consumption, preventing dramatic increases in postprandial 
blood glucose, which may possibly reduce adverse health effects associated with chronic 
hyperglycemia.84  
We have demonstrated the ability of RS to prevent hyperglycemia and associated diabetic 
complications in rodent models of T1DM and type 2 diabetes mellitus (T2DM). Attenuation or 
prevention of long-term diabetic complications may be a result of the protective effect of RS on 
kidney function and nutrient homeostasis. Complications associated with diabetes are highly 
associated with microvascular issues, causing deteriorating kidney function and therefore 
disrupting nutritional status. Using an RSII based diet as a replacement for cornstarch, we have 
observed attenuated DM-associated weight loss and hyperglycemia, prevented diabetic 
nephropathy as evidenced by normalized serum creatinine, urinary volume and urinary albumin 
excretion, prevented excretion of VBP and 25(OH)D3 and normalized gene expression of renal 
endocytic proteins megalin and dab2, respectively.55 
Resistant starch and the gut microbiome 
 RS is a notable substrate for fermentation of short chain fatty acids (SCFA’s) including 
butyrate, acetate and propionate in the colonic gut. Dietary RS has been shown to favor the 
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production of butyrate among other SCFA’s, however this largely depends on the type, amount 
and structure of RS, all of which can affect microbial fermentation and relative SCFA 
proportions. Typically, acetate represents the highest proportion (60%) among colonic SCFA’s 
and therefore acetate is the most abundant in peripheral circulation. However, peripheral 
circulation is generally low for these fermentable by-products.87  
SCFA’s have been associated with reduced inflammation in monocytes and peripheral blood 
mononuclear cells (PBMC), mediated by FFAR2 (immune cells) or FFAR3 (adipocytes) and 
normalization of cytokine/chemokine profiles and prostaglandin E2 (PGE2).87 Other studies have 
observed neutrophil and leukocyte recruitment stimulated by FFAR2 to alleviate bacterial-
associated inflammation. Low levels of SCFA’s are typically found in circulation, limiting anti-
inflammatory action  
Typically, there are low levels of SCFA’s found in circulation, limiting anti-inflammatory 
action to the colon. However, pathogenic bacteria are capable of producing SCFA’s throughout 
circulation and subsequently elevating peripheral concentrations. This hypothesis supports the 
immunological role of SCFA’s in the colonic gut, peripheral tissues and adipocytes. The action 
of SCFA’s in these tissues is significant given the inflammatory pathogenesis of T2DM and 
various gastrointestinal diseases.88  
 
  
	  	   32	  
CHAPTER 2: RESISTANT STARCH PROMOTES 
REGULATION OF METHYL GROUP METABOLISM 
Abstract 
Type 1 diabetes mellitus (T1DM) is an autoimmune disease characterized by pancreatic β 
cell dysfunction, insulin deficiency and abnormal carbohydrate metabolism. Chronic 
hyperglycemia causes structural damage to the kidneys, resulting in ultrafiltration and imbalance 
of nutrients such as vitamin D and disruption of various proteins associated with methyl group 
metabolism and homocysteine regulation.3-5 Using streptozotocin (STZ) treated rats as a model 
of T1DM, we have demonstrated that dietary resistant starch (RS) attenuates many complications 
associated with T1DM including increased urinary excretion of 25 hydroxyvitamin D3 
(25(OH)D3) and vitamin D binding protein (DBP).55  
The focus of this study was to characterize the impact of RS on methyl group metabolism 
using a STZ-induced diabetic rat model. Male Sprague Dawley rats (n=38) were randomly 
assigned to respective groups: control starch (CS, n=12), diabetes-CS (DM-CS, n=12) and 
diabetes-RS (DM-RS; n=14). CS and DM-CS rats were fed a standard cornstarch diet throughout 
the 9-wk study, whereas the DM-RS group was acclimated to the CS diet for 2-wk and 
transitioned to a high amylose RS diet (RS was 37% resistant to digestion) for the remaining 7-
wk. Rats were sacrificed, tissues were extracted and plasma and urine were collected for 
analysis. DM-RS rats exhibited symptoms characteristic to DM including polyuria, 
hyperglycemia and decreased urinary creatinine excretion (2.3 fold). In addition, glycine N-
methyltransferase (GNMT) activity was elevated in hepatic (1.2 fold) and renal (~2 fold) tissues. 
However, there was no change in ribonucleic acid (mRNA) abundance of one-carbon proteins 
GNMT and betaine-homocysteine S-methyltransferase (BHMT) in DM rats fed either diet. 
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Dietary RS prevented or attenuated DM-complications and normalized hepatic and renal GNMT, 
an important protein to one-carbon metabolism.  
 
Introduction 
Recent developments in nutritional sciences have geared researchers toward implementing 
therapeutic dietary strategies in the prevention and treatment of various pathologies including 
gastrointestinal conditions, neurological disorders and autoimmune diseases. Resistant starch 
(RS) is a type of dietary fiber that resists digestion in the small intestine and undergoes 
fermentation in the colon.89 Consumption of carbohydrates that are abundant in RS have 
exhibited many physiological and metabolic health benefits. Subsequently, RS has been widely 
used as a dietary preventative and treatment method for a variety of diseases including diabetes, 
cardiovascular disease, obesity and cancer.89  
Colonic fermentation of RS results in the production of short chain fatty acids (SCFA’s), 
proven as mediators in these pathological conditions. Gut hormones stimulated by SCFA’s are 
associated with increased energy expenditure and lipolysis in humans, which provides 
implications for RS in prevention and treatment of obesity, type 2 diabetes mellitus (T2DM) and 
metabolic syndrome. SCFA absorption in adipocytes is also linked to improved blood lipid 
profiles.89 Furthermore, SCFA have an immunological role by producing anti-inflammatory 
effects in the colonic gut, peripheral tissues and adipocytes. This mechanism has shown benefits 
in inflammatory-related diseases such as T2DM, gastrointestinal disorders and cancer.90 
The protective effect of RS in diabetes is likely related to several mechanisms. Dietary RS 
bypasses the small intestine, resisting typical carbohydrate digestion and absorption and assisting 
in glycemic control. Various studies have shown a reduction in post-prandial blood glucose 
associated with RS consumption.1,91-93 Due to the multitude of complications associated with 
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chronic hyperglycemia, the use of RS as a therapeutic dietary agent may provide favorable 
outlooks for diabetic patients, slowing and/or preventing the progression of these complications 
and inevitable mortality. Diabetic nephropathy is a common vascular disease of the kidneys 
associated with poor glycemic control in diabetes. Declining renal function results in 
hyperfiltration and reduced clearance of various proteins and nutrients associated with vitamin D 
metabolism and one-carbon metabolism.2,5 RS has previously shown to attenuate/prevent 
complications associated with uncontrolled hyperglycemia such as weight loss, increased urinary 
output and hyperfiltration of proteins and nutrients associated with declining renal function.55 
Most recently, we have shown RS to restore vitamin D status as evidenced by reduced vitamin D 
binding protein (DBP) and 25 hydroxyvitamin D3 (25(OH)D3) excretion and normalized 
expression of endocytic vitamin D receptors in the kidneys.55 
 Reduced homocysteine clearance and elevated plasma homocysteine levels are associated 
with chronic kidney disease (CKD) progression in DM.3 Subsequent induction of one-carbon 
regulatory proteins glycine N-methyltransferase (GNMT), betaine-homocysteine S-
methyltransferase BHMT, cystathionine beta synthase (CBS) and y-cystathionase have also been 
observed and hypothesized as compensatory mechanisms to maintain methyl group supply and 
normal homocysteine levels.6 In this study we hypothesized that RS supplementation would 
alleviate abnormalities in methyl group metabolism by controlling blood glucose and preserving 
kidney function.   
Materials and Methods 
Rodents. Animal studies were approved and conducted under the guidelines provided by the 
Iowa State University Laboratory Animal Resources. Male Sprague Dawley (N=38; Harlan 
Teklad, Madison, WI) rats weighing 110-140 g were housed individually in plastic-wired cages 
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under a 12-hr light:dark cycle. Rodents were housed for 9 wk and had access to food and water 
ad libitum.  
Diets. The standard control diet composition is listed in Table 2.1. High-amylose maize RS was 
used as a replacement for cornstarch. Cornstarch (CS) was replaced with RS, 37% resistant to 
digestion. Starches were cooked prior to mixing with other ingredients.   
Table 2.1 Diet Compositions 
Diet Ingredient Control (g/kg) RS (g/kg) 
  Casein, vitamin-free 200 200 
  Glucose 150 150 
  Cornstarch 550 0 
  Resistant Starch 0 550 
  Corn oil 50 50 
  Vitamin Mix (AIN93) 10 10 
  Mineral Mix (AIN93) 40 40 
  Methionine 3.0 3.0 
 Choline 2.0 2.0 
 
Treatment groups. Sprague Dawley rats were acclimated to the control diet for 14 d. Rats were 
then randomly divided into three groups, including control (group 1; n=12), diabetes mellitus 
(DM; group 2; n=12) and DM+RS (group 3; n=14). Following the acclimation period, group 1 
(control) and 2 (DM) were continued on the standard diet and groups 3 (RS) was transitioned to 
the RS diet. This summarizes the 3 groups and 2 diets that were administered over the 50 d 
experimental period.  
Streptozotocin injection. Following the acclimation period, rats transitioned to the diet regimen 
specified for each group for approximately 21 d. On d 35, diabetic rats (groups 3-6), were given 
an intraperitoneal injection of streptozotocin (STZ; 60 mg/kg BW) to induce diabetes. Control 
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rats (groups 1-2) were given a vehicle injection (10 mmol/L citrate buffer, pH 4.5). Rats were 
killed 3 wk post-STZ injection.  
Data collection. All rodents were housed in metabolic cages for urine collection and fasted 
overnight (12h) prior to the kill. A cocktail of ketamine:xylamine (90:10 mg/kg BW) was 
prepared and used to anesthetize rats via intraperitoneal injection. Whole blood was collected via 
cardiac puncture and centrifuged for plasma collection. After euthanasia, liver and kidney tissues 
were extracted and submerged in liquid nitrogen for preservation. Collected tissues, blood and 
urine were stored at -80°C for later analysis.  
Assessment of renal function. Urinary creatinine, serum creatinine and serum albumin 
concentrations were assessed using a commercial colorimetric kit (QuantiChrom Creatinine 
Assay Kit and QuantiChrom BCG Albumin Assay Kit; Bioassay Systems, Hayward, CA).  
Assessment of blood glucose. To assess blood glucose in all rats, fasting blood glucose (FBG) 
was measured via glucometer (Bayer Healthcare) using serum collected via cardiac puncture at 
the time of euthanasia.  
Assessment of DM symptoms. To assess weight loss and increased urinary output associated 
with DM, 12-hr urine samples were collected and measured prior to euthanasia. Body weight 
was determined daily throughout the study to calculate weight loss/gain following diet 
implementation and STZ injections in DM rats. 
Assessment of serum 25(OH)D3 status.  Vitamin D status was assessed by measuring serum 
25(OH)D3 using a commercial enzyme immunoassay kit (Immunodiagnostic Systems, 
Scottsdale, AZ).  
Enzyme analysis. GNMT activity was assessed in hepatic and renal tissues using the Cook and 
Wagner method94 with slight modifications. Each sample assay was performed in triplicate using 
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250 µg aliquots and combined with a reaction mix containing 0.2 M Tris buffer (pH 9.0), 0.2 
mM S-adenosyl-L-[methyl-3H]methionine (PerkinElmer, Waltham, MA), 2 mM glycine and 5 
mM dithiothreitol. A heat-killed control was prepared for triplicate samples and aliquots were 
incubated for 30 min at 25°C. The reaction was halted by the addition of 10% trichoroacetic acid 
and activated charcoal was added to aliquots, vortexed and centrifuged (14,000 x g) to remove 
excess, unreacted SAM. Supernatant layers were isolated and extracted to be used for liquid 
scintillation counting.  
Real-time PCR. Hepatic tissue was removed from -80°C storage and ~0.1g samples were cut 
and dispersed in Trizol Reagant (Invitrogen, Carlsbad, CA). RNA was isolated using SV Total 
RNA Isolation System (Promega, Madison, WI) and quantified via UV detection (Nanodrop, 
280/260). Extracted RNA was used for cDNA synthesis using a High Capacity cDNA synthesis 
kit with RNase inhibitor (Applied Biosystems, Foster City, CA). Reactions were performed in 
duplicate from single cDNA stocks created for each liver sample. Hepatic GNMT and BHMT 
gene expression was analyzed via real-time PCR using iScript SYBR Green Detection reagents 
(Bio-Rad, Hercules, CA), 4µL cDNA/well and forward and reverse primer sets for BHMT and 
GNMT using 18S mRNA as the control or housekeeping gene (Table 2.2). Gene expression was 
assessed via fold-induction relative to non-diabetic control rats.  
Statistical Analysis 
Statistics were calculated using SigmaPlot 9.0 software (Systat, Chicago, IL). Treatment group 
means were compared using a one-way ANOVA, followed by the Fisher least-significant 
difference post-test. ANOVA on ranks was performed when normality or equal variance tests 
failed. Significant differences were noted at P < 0.05.  
 
	  	   38	  
Results 
Serum 25(OH)D3 was moderately elevated in DM.  
No statistical differences between groups were yielded in this assay. However, 25(OH)D3 was 
moderately elevated in DM rats compared to control and RS-treated rats. This may be attributed 
to increased consumption of food, leading to increased vitamin D status.  
Dietary RS attenuated weight loss and hyperglycemia, and prevented polyuria. 
Weight loss. No statistical difference in cumulative weight gain was observed between groups 
prior to STZ-injection (Table 2.2). DM rats fed the control diet lost 27% of total body weight 
following STZ-injection, while control rats gained 11% of total body weight. DM rats fed the RS 
diet gained 1% of total body weight following STZ-injection (Figure 3.3). Hyperglycemia. 
Elevated blood glucose (527±52.2 mg/dL) was observed in DM rats at 9 wk 140% compared to 
CS blood glucose (221.6±17.1 mg/dL). Hyperglycemia was not prevented in RS rats, however 
there was a statistically significant 32% reduction in blood glucose (358.4±46.6 mg/dL) 
compared to the DM-CS group (p=0.008). Polyuria. Polyuria is evident in DM and is used as a 
marker for renal dysfunction. Urine was collected over a 12-hour period and measurements 
illustrated a 53% reduction in urinary volume of RS rats (6.7±1.9 mL) relative to DM rats 
(12.7±2.2 mL) fed CS diet (p=0.022). There were no statistically significant differences observed 
between the control and RS group (p=0.533) (Figure 2.5).  
Dietary RS normalized urinary creatinine excretion, but had no affect on serum creatinine 
or serum albumin concentrations. Decreased urinary creatinine levels were observed in DM 
group, ~60% lower than the control (p=0.006) (Figure 2.2A). RS normalized creatinine 
concentrations in the urine. No statistical differences were observed between DM-RS and CS 
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groups (p=0.434). There were no significant differences in serum creatinine concentrations 
(p=0.417; Figure 2.2B) or serum albumin concentrations (p=0.384) between groups (Figure 2.3). 
Dietary RS significantly decreased renal GNMT activity and attenuated hepatic GNMT 
activity. Hepatic GNMT Activity. Similar to other studies in our lab, GNMT activity was 
elevated in the liver of diabetic rats and significant differences were observed between all groups 
(p=0.027). This activity was not entirely normalized by RS, however there was a slight reduction 
(p=0.127).  Renal GNMT Activity. Renal GNMT Activity is generally lower compared to hepatic 
tissue. However, increased GNMT activity in DM groups was significantly reduced (23%) by the 
RS diet (p=0.039). There were no observable differences between the control and DM-RS groups 
(p=0.018).  
No differences in GNMT and BHMT mRNA expression in hepatic tissue found between 
groups. Induction of hepatic GNMT (~4 fold) and BHMT mRNA (2.1 fold) was illustrated in 
DM-CS rats relative to control. RS attenuated expression of both proteins (Figure 2.6), however 
the results were not statistically significant (Table 2.4).  
Discussion 
 Resistant starch has been confirmed as an effective dietary strategy for glycemic control and 
alleviation of complications characteristic of diabetes.1,55,91-93 We hypothesized that RS 
consumption would normalize abnormalities in methyl group metabolism regarding induction of 
key regulatory proteins GNMT and BHMT by diabetes. As demonstrated in previous studies, 
GNMT activity was elevated in kidney and liver tissues of diabetic rats. In addition, elevated 
hepatic mRNA expression of BHMT and GNMT was observed in DM rats.59,95,96 Previous 
research has shown the use of hormones and nutrients to normalize the expression of these 
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proteins in one-carbon metabolism.6 Similar results were obtained in this model, suggesting RS 
to be another mediator for these proteins.  
 Weight loss associated with prolonged hyperglycemia is a characteristic symptom of 
diabetes. Interestingly, the therapeutic use of RS has been used in many T2DM and obese 
models as a dietary method for weight loss.97,98 This mechanism is related to the production of 
GLP-1 (glucagon like peptide-1) by butyrate in the colonic gut and is associated with increased 
energy expenditure and lipolysis in humans.99 RS attenuated hyperglycemia and subsequently 
weight loss in this T1DM model, suggesting that this mechanism did not have a profound 
impact.  
Normal FBG in humans ranges between 70-100 mg/dL.33 However, glucose concentrations 
in rodents are much higher under fasting conditions. One study evaluated blood glucose after 5 
and 11 hours in Wistar rats, determining an average FBG between 135-190 mg/dL.100 Other 
studies have used 200 mg/dL and 250 mg/dL as benchmarks for DM classification.101 However, 
we have observed FBG exceeding 300 mg/dL in some control rats. Therefore it is important to 
evaluate other markers that can assess DM severity including serum creatinine, urinary albumin 
and polyuria.  
Polyuria, decreased serum creatinine and microalbuminuria are indicative of renal 
function.42 A model of diabetic nephropathy in mice showed elevated serum creatinine, with 
0.08-0.11 mg/dL classifying the normal range, with albumin:creatinine ratio >1000 mg/g.102 This 
dramatically exceeds ratios characterizing CKD in humans. There were no significant differences 
in serum creatinine concentrations found between groups and mean concentrations were below 
this normal range (0.501-0.519±0.0383 mg/dL). However, urinary creatinine and albumin 
concentrations are direct markers for impaired renal filtration and typically better standards to 
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use in CKD assessment.42 Urinary creatinine concentrations were depressed in DM rats, 
suggesting the perturbed clearance of this metabolite in the glomerulus. Polyuria and decreased 
urinary creatinine were evident in our study and both symptoms were alleviated in RS treated 
rats. 
In addition to these biomarkers, disruptions in vitamin D metabolism and methyl group 
metabolism are observed in diabetes. In our laboratory we have assessed the induction of key 
regulatory proteins GNMT, BHMT and cystathionine beta synthase (CBS) associated with 
diabetic nephropathy.59 Upregulation of these enzymes may be related to impaired homocysteine 
clearance by the proximal tubules and the subsequent rise in plasma homocysteine.3 
Transmethylation, transsulfuration and remethylation pathways in one-carbon metabolism are 
governed by homocysteine concentrations and the S-adenosylmethionine: S-
adenosylhomocysteine (SAM:SAH) ratio.61 Hyperhomocystenemia is a consequence of CKD 
and may be associated with the upregulation of these proteins and pathways. BHMT functions to 
remethylate methionine from homocysteine.60 In transmethylation, GNMT accepts and disposes 
methyl groups in the form of sarcosine.56 Transsulfuration enzymes CBS and γ-csytathione are 
also induced, allowing for the catabolism of homocysteine to cysteine.59 These mechanisms may 
help regulate methyl group supply and homocysteine in a diabetic state. However, increased 
catabolism of methyl groups via GNMT may lead to hypomethylation, as GNMT takes methyl 
groups from vital methyltransferases and impairs vital methylation reactions.   
 In this study, hepatic and renal GNMT activity were elevated and GNMT and BHMT 
mRNA abundance was markedly increased in DM rats. In our laboratory, administration of 
retinoic acid (RA), dexmathasone (DEX) and insulin has been shown to normalize the genomic 
expression of these proteins in DM rats. Insulin administration alleviated GNMT upregulation in 
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this diabetic model, suggesting the changes are diabetes-specific.6 Hormone insulin functions to 
bring blood glucose to homeostasis in diabetes.12 Therefore, normalization of GNMT could be 
attributed to the administration of insulin and/or the normalization of blood glucose. While 
previous studies have shown the prevention of diabetic nephropathy and associated 
complications using RS, we have observed these results in the presence and absence of 
hyperglycemia.55 Although this does not rule out the possibility of glucose as a hormonal 
modulator in one-carbon metabolism, it suggests another mechanism may be responsible.  
New developments in research have characterized the role of SCFA produced by RS in the 
colonic gut. SCFA’s are immunological mediators in the colon, peripheral tissues and 
adiopocytes. Acetate, butyrate and propionate exhibit an anti-inflammatory effect in the body in 
response to bacterial infections.88 Of particular interest is the role of butyrate as a mediator for 
TGF-β-1 (transforming growth factor-β-1), a profibric cytokine expressed during advanced renal 
disease and associated with renal fibrosis.103  
 
 
 
 
 
Figure 2.1: Renal fibrosis.104  
CKD is characterized by structural and functional changes to the renal tubules, ECM and 
glomerulus.3-5 Renal fibrosis occurs in the late stages of CKD and involves an inflammatory 
cascade that begins with an injury to the kidney. This stimulates the release of pro-inflammatory 
cytokines, which recruit macrophages and T cells for infiltration at the site of injury.  The 
activation of fibroblasts, mesangial cells and epithelial cells leads to the accumulation of 
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collagen, fibrinogen and other matrix components. Excessive accumulation in the extracellular 
matrix (ECM) leads to cross-linking, excessive scarring and loss of renal function.104 
 Cytokine TGF-β-1 and its associated similar to mothers against decapentaplegic (SMAD) 
receptors are upregulated in CKD. In healthy kidneys, TGF-β-1 is tightly regulated by SMAD 
antagonists, which include ski-related novel N (SnoN), Sloan-Kettering Institute (Ski) and TG-
interacting factor (TGIF). Recent studies have demonstrated low circulating levels of these 
antagonists in CKD, leading to amplified expression of this cytokine. Additionally, this cytokine 
is regulated via induction and post-translational modification.104 Potential modulators of TGF-β-
1 include elevated glucose, angiotensin II and butyrate. Together this potentiates glucose and RS 
in the form of butyrate, as hormonal and nutritional modulators in diabetes.  
 Mechanisms by which glucose mediates this pro-inflammatory cytokine involve a variety of 
reactions. AGEs associated with chronic hyperglycemia stimulate the production of ROS.1 
Circulating ROS activates protein kinase C (PKC), the hexosamine pathway, extracellular signal-
related kinase (ERK) pathway, p38 mitogen activated protein kinase (MAPK) pathway and TGF-
β-1 transcription factors. Specifically PKC and the hexosamine pathway are related to glucose-
stimulated TGF-β-1 synthesis.104 Interestingly, recent developments have highlighted butyrate in 
the mitigation of TGF-β-1 stimulated renal fibrosis by inhibiting MAPK and ERK pathways.103 
Taken together, these results have indicated that both glucose and RS are mediators in DM. 
Moreover, RS in the form of butyrate exhibits a protective effect in the kidneys of diabetic 
patients, preventing the progression of CKD and associated complications.  
  Collectively, our study demonstrated the prevention/attenuation of diabetic complications 
with the use of dietary RS. New developments in research have suggested butyrate to play an 
immunological role in in CKD as in inhibits several pathways related to renal fibrosis and TGF-
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β-1 synthesis. Because RS supplementation attenuates hyperglycemia in DM rats, the production 
of butyrate by RS directly and indirectly mediates these inflammatory processes characteristic in 
DM. The protective effect of RS in the kidneys thus prevents a multitude of complications 
including weight loss, polyuria, hyperfiltration of proteins and nutrients and altered clearance of 
metabolites. In this study, we have demonstrated the normalization of key regulatory proteins in 
methyl group metabolism, speculating RS as an indirect modulator in one-carbon metabolism. 
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Table 2.2 Real-time RT-PCR primers 
Target     Primers 
 
GNMT      F*:  ACA ACA AAG CCC ACA TGG TAA CCC 
       R*:  AGC CGA AAC TTA CTG AAG CCA GGA 
 
BHMT      F:  ATC TGG GCA GAA GGT CAA TGA AGC 
       R:  TGA CTC ACA CCT CCT  GCA ACC AAT 
 
18S       F:  GAA CCA GAG CGA AAG CAT TTG CCA 
       R:   ATG GTC GGA ACT ACG ACG GTA TCT 
*F represents forward primer, R represents reverse primer 
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Figure 2.2: Creatinine concentration in urine (A) and serum (B). RS normalized urinary 
creatinine concentrations in DM rats. No statistical differences were observed between DM-RS 
and CS groups (p=0.434). 
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Figure 2.3: RS diet has no effect on serum albumin concentrations in DM rats. There were 
no significant differences in serum albumin concentrations between groups (p=0.384)	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Figure 2.4: RS significantly reduces hyperglycemia associated with DM. Elevated blood 
glucose was observed in DM rats at 9 wk 140% compared to blood glucose in control rats.  
Hyperglycemia was not prevented in RS rats, however there was a statistically significant 32% 
reduction in blood glucose compared to the DM-CS group (p=0.008).	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Table 2.2: RS diet significantly reduces weight loss associated with DM after STZ injection 
 
 
 
Total Weight Gain to STZ (42 d), g 
 
Total Weight Gain after STZ (21 d), g 
 
Control 
 
202±6.7a 
 
30.0±2.4a 
 
DM-CS 
 
208±4.1a 
 
-62.4±7.6b 
 
DM-RS-37 
 
P Value 
 
212±5.1a 
 
0.420 
 
-1.4±7.1c 
 
                                     <0.001 
 
Data shown as group mean ±SE; letters denote significant differences between groups (p<0.05) 
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Figure 2.5: Cumulative weight loss/gain. . No statistical difference in cumulative weight gain 
observed between groups prior to STZ-injection. DM-CS rats lost 27% of total body weight 
following STZ-injection, while control rats gained 11% of total body weight. DM-RS rats gained 
1% of total body weight following STZ-injection. Data shown as group mean ±SE; letters 
indicate significant differences between groups (p<0.05); dotted lines indicate diet transition and 
STZ injection at 14 d and 43 d, respectively. 
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Figure 2.6: RS prevents polyuria in DM rats. Following a 12-hr fasting period, there was a 
53% reduction in urinary volume of DM-RS rats (6.7±1.9 mL) relative to DM-CS rats (12.7±2.2 
mL; p=0.022). No statistically significant differences were observed between the CS and DM-RS 
group (p=0.533) 
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Table 2.3: RS diet normalizes renal GNMT activity and attenuates increased hepatic GNMT 
activity associated with the diabetic condition 
 
Renal GNMT Activity, pmol/min*mg 
 
Liver GNMT Activity, pmol/min•mg 
 
CS 
 
5.1±0.7a 
 
23.6±1.1a 
 
DM-CS 
 
9.1±0.9b 
 
29.2±1.5b 
 
DM-RS-37 
 
P Value 
 
7.0±0.4a 
 
0.027* 
 
26.4±1.3a,b 
 
0.027* 
 
Data are means ±SE (n=x); letters denote significant differences between groups (p<0.05) 
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Figure 2.7: Hepatic and renal GNMT activity. GNMT activity was elevated DM liver and 
kidney tissues and significant differences were observed between all groups (p=0.027). GNMT 
activity was not normalized by RS in the liver. However, Renal GNMT activity in DM groups 
was significantly reduced (23%) by the RS diet (p=0.039). Data shown as group mean ±SE; 
letters indicate significant differences between groups (p<0.05)  
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Table 2.4: Hepatic mRNA abundance of one-carbon metabolism enzymes in diabetic rats fed CS 
and RS diets relative to control rats.  
 
Hepatic GNMT mRNA Relative 
Expression 
 
Hepatic BHMT mRNA Relative 
Expression 
 
CS 
 
1.0±0.1a 
 
1.1±0.2a 
 
DM-CS 
 
3.9±2.8a 
 
2.3±0.7a 
 
DM-RS-37 
 
P Value 
 
1.8±0.9a 
 
0.307 
 
1.5±0.3a 
 
0.739 
 
Data are means ±SE (n=x); letters denote significant differences between groups (p<0.05) 
GNMT Abundance BHMT Abundance
M
ea
n 
fo
ld
 c
ha
ng
e 
in
 B
H
M
T 
an
d 
G
N
M
T
 m
R
N
A
 e
xp
re
ss
io
n 
(f
ol
d 
of
 c
on
tro
l)
0
2
4
6
8
10
CS 
DM-CS 
DM-RS 
 
Figure 2.8: Hepatic GNMT and BHMT mRNA abundance relative to the control. There 
were no statistically significant reductions in GNMT and BHMT mRNA expression with RS 
administration; letters indicate significant differences between groups (p<0.05) 
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General Conclusion 
Type 1 diabetes mellitus (T1DM) is an autoimmune disease that manifests from a 
combination of genetic, epigenetic and environmental factors. This disease is characterized by 
insulin deficiency, impaired carbohydrate metabolism and subsequent hyperglycemia. Chronic 
hyperglycemia associated with uncontrolled DM causes progression of microvascular and 
macrovascular complications characteristic of the disease. Advanced glycation end products 
(AGEs) associated with hyperglycemia infiltrate microvascular tissues, ultimately leading to 
vascular disease of the nervous system, eyes and kidneys.1  
Diabetic nephropathy is one of the most common complications associated with DM and the 
leading cause of chronic kidney disease.2 Approximately, 40% of diabetic individuals progress 
from diabetic nephropathy to CKD and end stage renal failure (ESRF) during their lifetime.41 
CKD is associated with numerous pathologies including cardiovascular disease (CVD), vitamin 
D deficiency and impaired methyl group metabolism. There are several mechanisms that link 
CKD and CVD including hypertension, endothelial dysfunction and hyperhomocystenemia.5 
Hypertension contributes to the progression of CKD and is also a consequence of the 
disease. Renal dysfunction causes hypertension in diabetic patients by 1) disrupting sodium and 
volume concentrations that are correlated with blood pressure 2) causing autonomic 
dysregulation, which leads to increased peripheral resistance, blood volume, cardiac output and 
subsequently increased blood pressure and 3) activating the renin-angiotensin system (RAS) 
which may lead to an inappropriate rise in blood pressure.105 RAS activation also contributes to 
endothelial dysfunction and the development of CVD by activating Angiotensin II. Angiotensin 
II and circulating AGEs stimulate the production of inflammatory factors and reactive oxygen 
species (ROS), which directly contribute to endothelial dysfunction and atherosclerosis.5,46  
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Figure 2.9: Chronic kidney disease and hypertension contribute to cardiovascular disease risk106 
 
Structural damage to the nephron paired with endothelial dysfunction leads to increased 
vascular permeability and impaired filtration of proteins and many other nutrients.5 Loss of renal 
function has been linked to vitamin D deficiency and hyperhomocystenemia.2,5,54 Structural 
damage to the glomerulus causes hyperfiltration of nutrients including vitamin D binding protein 
(DBP), 25 hydroxyvitamin D3 (25(OH)D3) and vitamin D endocytic receptors megalin, cubilin 
and dab2.2,54 Vitamin D deficiency can lead to anemia, osteoporosis, cancer and autoimmune 
diseases.49 
Impaired glomerular filtration may also cause decreased clearance of nutrients including 
homocysteine, a key metabolite in methyl group metabolism. Decreased homocysteine clearance 
can lead to the subsequent rise in plasma homocysteine levels. Hyperhomocystenemia is an 
independent risk factor for CVD and is highly correlated with declining glomerular filtration rate 
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(GFR) in severe CKD. Anomalous upregulation of pathways and proteins in one-carbon 
metabolism are also associated with severe CKD. Researchers postulate these alterations as 
compensatory mechanisms for changes in homocysteine concentrations. 3 Induction of key 
proteins glycine-N-methyltransferase (GNMT) and betaine-homocysteine-metyltransferase 
(BHMT) in CKD can lead to methyl group wastage and subsequent hypomethylation, which is 
associated with many adverse health conditions including cancer, neurological disorders, birth 
defects and CVD. 57,58 
Diabetes mellitus (DM) affects approximately 180 million individuals nationally, with 5% 
of individuals living with T1DM.11 Uncontrolled hyperglycemia in DM can prime the 
development of many other diseases including CKD, vitamin D deficiency, cancer, neurological 
disorders and CVD. Therefore, prevention and treatment of this disease is imperative for optimal 
quality of life and longevity in diabetic patients. Many therapeutic dietary strategies have been 
developed and used in research to determine their affect in DM control including high fiber diets, 
lower glycemic index diets, prebiotics and probiotics.107 Resistant starch (RS) is a dietary fiber 
that resists digestion, bypasses the small intestine and undergoes fermentation in the colonic 
gut.85 RS consumption slows digestion and absorption of glucose, acting as a lower glycemic 
agent to prevent dramatic increases in post-prandial blood glucose.84 Attenuated hyperglycemia 
associated with RS consumption may possibly reduce the development of comorbidities related 
to uncontrolled DM. 
 Previous research in conjunction with this study has demonstrated the ability of RS to 
attenuate hyperglycemia and therefore prevent diabetic complications and abnormalities 
associated with vitamin D metabolism and methyl group metabolism.55 Proposed mechanisms 
for this phenomenon include the normalization of blood glucose and/or the production of 
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butyrate by RS in the colon, which acts as an immunological modulator in CKD.6,88 The 
protective effect of RS in diabetes and other pathological conditions presents many positive 
implications in health and disease.89,90 
In addition to promoting blood glucose homeostasis, RS has been shown to 1) improve 
satiety due to a slower rate of digestion 2) increase lipid oxidation and energy expenditure 3) 
improve colonic mucosal integrity and reduce inflammation via immunological effects exerted 
by butyrate and other SCFA’s produced during RS fermentation and 4) improve insulin 
sensitivity.108 With these health benefits, RS may be used as a treatment for various disease 
states such as T2DM, colon cancer, CVD, inflammatory gastrointestinal conditions and 
autoimmune diseases. RS has a dramatic impact on the gut microflora by promoting microbiome 
activity and diversity and producing SCFA’s, both linked to disease prevention. Researchers are 
working to better understand how RS and other carbohydrates influence the gut microflora. The 
mechanism behind these physiological benefits may be directly attributed to specific bacterial 
populations produced by RS.107  
There are many risk factors associated with T1DM including age, family history, genetic 
susceptibility and environmental factors such as vitamin D deficiency and viruses.19 More 
recently, research has geared toward understanding the role of the immune system in disease 
development as it relates to the gut microbiome. T1DM is associated with increased intestinal 
permeability, gut leakiness and altered intestinal immunity.109 Prebiotics and probiotics have 
immunomodulatory properties in disease, promoting optimal microbial diversity and exerting 
anti-inflammatory effects in the body.110  
The gut microbiome hosts a plethora of bacteria, capable of producing both pro- and anti-
inflammatory responses. Therefore, the composition of the microflora may be inherently related 
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to immune system functioning and disease development.111 In a recent study, researchers 
performed a gut microbiome analysis in non-obese diabetic rats, finding low abundance of 
healthy bacteria and decreased diversity of the microbiome. The bacterial strains observed in this 
study differed significantly compared to the gut composition of control rats. Control rats 
possessed probiotic bacterial species that have been shown to promote gut integrity and prevent 
autoimmunity such as Lactobacillus and Bifidobacterium.112 Another study investigated the gut 
microbiome in genetically susceptible children, whom possessed at least two islet autoantibodies. 
Similar results were obtained in this human model including 1) comprised gut integrity 2) low 
bacterial diversity 3) gut instability, defined as decreased similarity between gut microflora in 
autoimmune children and 4) altered ratio of Firmicutes to Bacteroidetes, the most notable 
differences between control and autoimmune microbiomes.112  
The mechanisms that link T1DM with the autoimmune microbiome are variable. Some 
researchers suggest that these bacteria may be more highly exposed to foreign substances, given 
the increased gut permeability and leakiness associated with the disease. Interaction between the 
autoimmune gut microbiome and pathogenic GI bacteria can result in altered T cell regulation 
and increased production of pro-inflammatory factors, preceding the autoimmune event that 
characterizes T1DM.109 These research studies have classified the autoimmune microbiome in 
T1DM and have identified plausible mechanisms that contribute to disease development.  
Several studies have investigated the use of prebiotics and probiotics as a means to 
normalize the gut microbiome and prevent occurrence of disease. In an NOD model, researchers 
observed reduced insulinitis, beta cell destruction and decreased incidence of T1DM with 
probiotic administration.113 Additionally, prebiotics such as RS have been shown to positively 
alter the microbial composition of the gut, promoting gut integrity and preventing bacterial 
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invasion.114,115 These results suggest that probiotics and prebiotics may be optimal dietary 
strategies in the treatment and prevention of various pathologies including diabetes, obesity and 
gastrointestinal disorders.   
Collectively, these research findings suggest the microbiome and immune system to be 
critical epigenetic factors in the development of T1DM. 116 This provides positive implications 
for administration of probiotics and prebiotics as a means to normalize the gut microbiome and 
prevent the onset of T1DM in susceptible individuals. Overall, research suggests that RS may be 
implemented as a therapeutic dietary aid for prevention and treatment of T1DM.  
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